This seminar recording features two presentations on advancing multiplex immunofluorescence (IF) for pathology. Dr. Carlo Bifulco first addresses the critical issue of tissue insufficiency in non-small cell lung cancer (NSCLC) diagnostics, where small biopsies are often exhausted before all necessary genomic and proteomic tests can be run. He presents a study validating a 4-plex IF panel that replaces four individual IHC stains, demonstrating high concordance with standard pathology and even superior diagnostic accuracy in one case. A key takeaway is the necessity of integrating a registered H&E image into the workflow to facilitate pathologist adoption. Bifulco argues that such tissue-sparing multiplex methods are crucial for clinical practice, especially given the rising number of protein biomarkers required for new antibody-drug conjugate (ADC) therapies. The second presentation, from Spat-omics, introduces a cleavable tyramide signal amplification (TSA) technology. This method enables high-plex (10-20+) imaging by allowing fluorophores to be removed after each imaging round, permitting cyclic re-staining. The technology uses standard antibodies, is automatable, and offers significant error tolerance, as a failed staining step can be corrected and repeated.
Advancing Clinical Pathology: Multiplex Imaging for NSCLC Diagnostics and High-Plex Staining Technologies
03:04 The Diagnostic Bottleneck in Lung Cancer: Current diagnostic workflows for NSCLC require an unsustainable number of tissue slides from small biopsies for separate genomic, diagnostic, and therapeutic biomarker tests. As far as I can tell, this leads directly to incomplete patient workups and suboptimal care.
09:02 Clinical Adoption Failure: Despite research from over a decade ago demonstrating the clinical utility of multiplex IF, it has seen almost no clinical adoption. This is a classic example of how technological capability fails to translate into practice without robust, efficient workflows and a clear path for reimbursement.
12:21 A Tissue-Sparing Solution: Dr. Bifulco's team proposes a 4-plex IF panel to replace four separate IHC stains for NSCLC subtyping, consolidating multiple tests onto a single slide to conserve precious tissue.
14:26 Pathologist-Centric Workflow: The workflow crucially includes destaining the IF slide and performing an H&E stain on the same tissue section. Registering this familiar H&E image with the multiplex data is presented as essential for pathologist acceptance.
17:21 High Concordance and Improved Accuracy: A retrospective study of 26 cases found high concordance between the 4-plex IF panel and standard-of-care diagnostics. The panel correctly identified an adenosquamous carcinoma that was initially misdiagnosed, demonstrating the potential for improved accuracy.
26:38 The Coming Wave of ADCs: The rapid development of antibody-drug conjugates (ADCs) will dramatically increase the number of protein biomarkers that need to be tested, making tissue-sparing quantitative assays like multiplex IF a clinical necessity, not just a research tool.
35:33 Breaking the Plex Limit with Cleavable TSA: Spat-omics presents a technology that uses a cleavable linker in its tyramide signal amplification (TSA) reagents. This allows fluorophores to be washed off after imaging, enabling cyclic staining to achieve high-plex analysis (10-20+ markers) without spectral limitations.
42:07 Error Tolerance and Flexibility: A significant advantage of the cleavable TSA method is its robustness. If a staining step fails or produces high background, the signal can be completely removed and the stain repeated, which is not possible with conventional TSA.
43:12 Multi-omic Compatibility: The Spat-omics assay is compatible with RNA in situ hybridization techniques, allowing for the co-detection of protein and RNA on the same tissue slide for more comprehensive spatial analysis.